Experimental gene therapy: The transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice

AIDS

Volumn 11, Issue 8, 1997, Pages 977-986

  Sanhadji, Kamel ^a   Leissner, Philippe ^b   Firouzi, Reza ^a   Pelloquin, François ^c   Kehrli, Laurence ^a   Marigliano, Martine ^b   Calenda, Valérie ^b   Ottmann, Michèle ^a   Tardy, Jean Claude ^d   Mehtali, Majid ^b   Touraine, Jean Louis ^a  

^a INSERM   (France)

^b TRANSGENE S A   (France)

^c Rockefeller Department of Medicine   (France)

^d Laboratory of Virology   (France)

Author keywords

Animal models; Antiviral therapy; Gene therapy; Interferon; SCID mice

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; TRANSACTIVATOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; EXPRESSION VECTOR; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA CELL LINE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; VIRUS REPLICATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; GENE PRODUCTS, TAT; GENE THERAPY; HIV-1; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; INTERFERON-BETA; MICE; MICE, SCID; TUMOR CELLS, CULTURED;

EID: 8244260604     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199708000-00005     Document Type: Article

References (49)

1. Anderson WF: Human gene therapy. Science 1992, 256:808-813.
2. McCarthy M: Gene therapy for HIV infection. Lancet 1993, 342:799.
3. Liem SE, Ramezani A, Li X, Joshi S: The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum Gene Ther 1993, 4:625-634.
4. Bahner I, Zhou C, Yu X-I, Hao Q-L, Guatelli JC, Kohn DB: Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol 1993, 67:3199-3207.
5. Malim MH, Freimuth WW, Liu J, et al.: Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 1992, 176:1197-1201.
6. Trono D, Feinberg MB, Baltimore D: HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989, 59:113-120.
7. Smythe JA, Sun D, Thomson M, et al.: A Rev-inducible mutant Gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA 1994, 91:3657-3661.
8. Yamada O, Yu M, Yee JK, Kraus G, Looney D, Wong-Staal F: Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther 1994, 1:38-45.
9. Lisziewicz J, Sun D, Smythe J, et al.: Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Natl Acad Sci USA 1993, 90:8000-8004.
10. Cagnon L, Cucchiarini M, Lefebvre JC, Doglio A: Protection of a T-cell line from human immunodeficiency virus replication by the stable expression of a short antisense RNA sequence carried by a shuttle RNA molecule. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:349-358.
11. Vandendriessche T, Chuah MK, Chiang L, Chang HK, Ensoli B, Morgan RA: Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol 1995, 69:4045-4052.
12. Caruso M, Klatzmann D: Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc Natl Acad Sci USA 1992, 89:182-186.
13. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA: Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 1995, 14:1542-1551.
14. Chen SY, Khouri Y, Bagley J, Marasco WA: Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with human anti-gp120 antibody. Proc Natl Acad Sci USA 1994, 91:5932-5936.
15. Samuel CE: Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 1991, 183:1-11.
16. Francis ML, Meltzer MS, Gendelman HE: Interferons in the persistence, pathogenesis, and treatment of HIV infection. AIDS Res Hum Retroviruses 1992, 8:199-207.
17. Turpin JA, Fan SX, Hansen BD, et al.: Regulation of HIV replication in monocytes by interferon. Prog Mol Subcell Biol 1994, 14:222-241.
18. Meylan PRA, Guatelli JC, Munis JR, Richman DD, Kornbluth RS: Mechanisms for the inhibition of HIV replication by interferons-α, -β, and -γ in primary human macrophages. Virology 1993, 193:138-148.
19. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: a Laboratory Manual (2nd edn), Edited by Nolan C. Cold Spring Harbor: Cold Spring Harbour Laboratory; 1989.
20. Tessier LH, Sondermeyer P, Faure T, et al.: Influence of mRNA primary and secondary structure on human IFN-g gene expression in E. coli. Nucleic Acids Res 1984, 12:7663-7676.
21. Kieny MP, Lathe R, Lecocq JP: New versatile cloning and sequencing vectors based on bateriophage M13. Gene 1983, 26:91-99.
22. Mehtali M, Munschy M, Caillaud JM, Kieny MP: HIV-1 regulatory genes induce AIDS-like pathologies in transgenic mice. In Retroviruses of Human AIDS and Related Animal Diseases. Edited by Girard M, Valette L. Lyon: Fondation M. Mérieux: 1992:25-30.
23. Vara JA, Portela A, Ortin J, Jimenez A: Expression in mammalian cells of a gene from Streptomyces alboniger conferring puromycin resistance. Nucleic Acids Res 1986, 14:4617-4624.
24. Barré-Sinoussi F, Chermann JC, Rey F, et al.: Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
25. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter JW: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979, 18:5294-5299.
26. Nara PL, Hatch WC, Dunlop NM, et al.: Simple, rapid, quantitative, syncytium-forming microassay for detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses 1987, 3:283-302.
27. Schwartz O, Henin Y, Marechal V, Montagnier L: A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res Hum Retroviruses 1988, 4:441-448.
28. Bednarik DP, Mosca JD, Raj NBK, Pitha PM: Inhibition of human immunodeficiency virus (HIV) replication by HIV transactivated alpha 2-interferon. Proc Natl Acad Sci USA 1989, 86:4958-4962.
29. Vieillard V, Lauret E, Rousseau V, De Maeyer E: Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express interferon beta. Proc Natl Acad Sci USA 1994, 91:2689-2693.
30. Vieillard V, Lauret E, Magner V, et al.: Autocrine interferon-β synthesis for gene therapy of HIV infection: increased resistance to HIV-1 in lymphocytes from healthy and HIV-infected individuals. AIDS 1995, 9:1221-1228.
31. Emerman M, Guyader M, Montagnier L, Baltimore D, Muesing MA: The specificity of human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. EMBO J 1987, 6:3755-3760.
32. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL: The SCID-hu mouse: murine model for the analysis of the human hematolymphoid differentiation and function. Science 1988, 241:1632-1639.
33. Bosma MJ, Carroll AM: The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 1991, 9:323-350.
34. Sanhadji K, Chargui J, Touraine JL: Long-term chimera produced by transplantation of human fetal liver cells into severe combined immunodeficiency mouse. Transplant Proc 1993, 25:452.
35. Kollman TR, Kim A, Pettoello-Mantovani M, et al.: Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice. J Immunol 1995, 154:907-921.
36. Kaneshima H, Su L, Bonyhadi ML, Connor RI, Ho DD, McCune JM: Rapid-high, syncylium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J Virol 1994, 68:8188-8192.
37. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, Spector SA: Human immunodeficiency virus infection of human-PBL-SCID mice. Science 1991, 251:791-794.
38. Aldrovandi GM, Feuer G, Gao L, et al.: The SCID-hu mouse as a model for HIV-1 infection. Nature 1993, 363:732-736.
39. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, McCune JM: Infection of the SCID-hu mouse by HIV-1. Science 1988, 242:1684-1686.
40. Aldrovandi GM, Zack JA: Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mouse. J Virol 1996, 70:1505-1511.
41. McCune JM, Namikawa R, Shih C-C, Rabin L, Kaneshima H: Suppression of HIV infection in AZT-treated SCID-hu mice. Science 1990, 247:564-566.
42. Parren PWH, Ditzel HJ, Gulizia RJ, et al.: Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 1995, 9:F1-F6.
43. Coccia EM, Krust B, Hovanessian AG: Specific inhibition of viral protein synthesis in HIV infected cells in response to interferon treatment. J Biol Chem 1994, 269:23087-23094.
44. Hansen BD, Nara PL, Maheshwari RK, et al.: Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. J Virol 1992, 66:7543-7548.
45. Kornbluth RS, Oh PS, Munis, JR, Cleveland PH, Richman DD: The role of interferons in the control of HIV replication in macrophages. Clin Immunol Immunopathol 1990, 54:200-219.
46. Poli G, Biswas P, Fauci AS: Interferons in the pathogenesis and treatment of human immunodeficiency virus infection. Antiviral Res 1994, 24:221-233.
47. Nabel GJ, Fox BA, Post L, Thompson CD, Woffendin C: A molecular genetic intervention for AIDS: effects of a transdominant negative form of Rev. Hum Gene Ther 1994, 5:79-92.
48. Woffendin C, Ranga U, Yang Z, Xu L, Nabel GJ: Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 1996, 93:2889-2894.
49. Miller DA, Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 1989, 7:980-990.